Skip to Content

Orion Oyj Class B ORINF

Morningstar Rating
$47.16 +9.72 (25.96%)
View Full Chart
Unlock our analysis with Morningstar Investor

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

ORINF is trading at a 289% premium.
Price
$38.27
Fair Value
$65.18
Uncertainty
High
1-Star Price
$18.52
5-Star Price
$88.14
Economic Moat
Jgw
Capital Allocation
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if ORINF is a good fit for your portfolio.

News

Trading Information

Previous Close Price
$37.44
Day Range
$47.1647.16
52-Week Range
$37.0047.16
Bid/Ask
$41.74 / $48.16
Market Cap
$6.63 Bil
Volume/Avg
6,734 / 6,649

Key Statistics

Price/Earnings (Normalized)
26.76
Price/Sales
4.34
Dividend Yield (Trailing)
4.55%
Dividend Yield (Forward)
4.55%
Total Yield
4.86%

Company Profile

Orion Oyj is a globally operating Finnish pharmaceutical company that develops, manufactures, and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients. The company predominantly focuses on treatments for central nervous system disorders, oncology, and respiratory diseases. Orion's customers include specialists and general practitioners, veterinarians, pharmacies, hospitals, and laboratories. Orion mainly serves Finland but also has a presence in other European countries, North America and other countries.
Sector
Healthcare
Industry
Drug Manufacturers - General
Stock Style Box
Mid Growth
Total Number of Employees
3,600

Comparables

Valuation

Metric
ORINF
OKDAV
PROC
Price/Earnings (Normalized)
26.7664.3680.81
Price/Book Value
6.061.217.05
Price/Sales
4.340.120.61
Price/Cash Flow
26.127.165.46
Price/Earnings
ORINF
OKDAV
PROC

Financial Strength

Metric
ORINF
OKDAV
PROC
Quick Ratio
1.000.520.97
Current Ratio
1.780.781.47
Interest Coverage
91.53−4.182.77
Quick Ratio
ORINF
OKDAV
PROC

Profitability

Metric
ORINF
OKDAV
PROC
Return on Assets (Normalized)
15.32%−2.54%0.21%
Return on Equity (Normalized)
26.75%−13.79%7.45%
Return on Invested Capital (Normalized)
21.52%−7.46%10.39%
Return on Assets
ORINF
OKDAV
PROC
See how this stock stacks up to its competitors with Morningstar Investor

Drug Manufacturers - General Industry Comparables

1-Day Chart
Name
Price
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
Eli Lilly and Co
LLY
FpwhrnzfkqTwhl$724.5 Bil
Johnson & Johnson
JNJ
PtptnmtrkWvwd$386.7 Bil
AbbVie Inc
ABBV
KqjlrkkqFmzc$327.0 Bil
Merck & Co Inc
MRK
ZvnkjmrnSfdj$317.3 Bil
Roche Holding AG ADR
RHHBY
PqnwfrpjsDwjx$261.9 Bil
AstraZeneca PLC ADR
AZN
ZsprkyhfjWtzs$242.7 Bil
Novartis AG ADR
NVS
DmptfgrnRxmw$224.0 Bil
Amgen Inc
AMGN
HbvwgdcbjFgh$179.6 Bil
Pfizer Inc
PFE
JxnyhylzzDjmr$174.4 Bil
Sanofi SA ADR
SNY
TdhcgyrgChq$131.7 Bil

Sponsor Center